FIELD: medicine, virology. SUBSTANCE: invention proposes a drug for treatment of patients with viral infections. An agent is a lyophilizate or isotonic solution. Lyophilizate has the following components: recombinant interferon-alpha-2 (2.5-10) x 105 IU and also, mg: phosphatidylcholine 60-80; cholesterol 6-10; alpha-tocopherol 6-10; ascorbic acid 1-2, and sucrose 40-90. An agent is stable in gastroenteric tract and absorbed in proximal part of small intestine. Agent is stable and does not hydrolyzed during absorption and has no show adverse effects. EFFECT: enhanced therapeutic effectiveness at oral intake. 1 tbl, 8 ex
Authors
Dates
1998-12-20—Published
1996-04-19—Filed